Cardiff Oncology (NASDAQ:CRDF) Price Target Increased to $15.00 by Analysts at HC Wainwright

Cardiff Oncology (NASDAQ:CRDF – Get Rating) had its price objective increased by HC Wainwright from $14.00 to $15.00 in a research report report published on Tuesday morning, The Fly reports.

Cardiff Oncology Trading Up 7.6 %

Shares of CRDF stock opened at $1.85 on Tuesday. The company has a market cap of $82.66 million, a price-to-earnings ratio of -2.08 and a beta of 1.73. The stock has a 50 day simple moving average of $1.70 and a 200-day simple moving average of $1.69. Cardiff Oncology has a 12-month low of $1.13 and a 12-month high of $3.41.

Cardiff Oncology (NASDAQ:CRDF – Get Rating) last issued its earnings results on Thursday, March 2nd. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.05. The business had revenue of $0.13 million during the quarter, compared to the consensus estimate of $0.08 million. Cardiff Oncology had a negative return on equity of 32.95% and a negative net margin of 10,033.16%. On average, equities analysts forecast that Cardiff Oncology will post -1.12 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Cardiff Oncology

A number of institutional investors and hedge funds have recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in shares of Cardiff Oncology by 10.6% in the 3rd quarter. Vanguard Group Inc. now owns 1,942,048 shares of the company’s stock worth $2,990,000 after acquiring an additional 186,392 shares during the period. BlackRock Inc. grew its holdings in shares of Cardiff Oncology by 11.5% in the 3rd quarter. BlackRock Inc. now owns 749,098 shares of the company’s stock worth $1,153,000 after acquiring an additional 77,131 shares during the period. Renaissance Technologies LLC grew its holdings in shares of Cardiff Oncology by 48.1% in the 2nd quarter. Renaissance Technologies LLC now owns 727,616 shares of the company’s stock worth $1,601,000 after acquiring an additional 236,158 shares during the period. Laurion Capital Management LP acquired a new stake in shares of Cardiff Oncology in the 2nd quarter worth approximately $1,589,000. Finally, State Street Corp grew its holdings in shares of Cardiff Oncology by 1.6% in the 1st quarter. State Street Corp now owns 704,237 shares of the company’s stock worth $1,747,000 after acquiring an additional 10,792 shares during the period. Institutional investors and hedge funds own 17.75% of the company’s stock.

Cardiff Oncology Company Profile

(Get Rating)

Cardiff Oncology, Inc is an oncology therapeutics company, which engages in the development of drugs that target mitosis for the treatment of various types of cancer. It is focused on developing onvansertib, a first-in-class, third-generation Polo-like Kinase 1 (PLK1) inhibitor, in combination with standard-of-care chemotherapy and targeted therapeutics.